Hollis-Eden To Testify On Radioprotectant Drug R&D Incentives At House Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
The maker of the radiation therapy Neumune is expected to discuss how federal procurement programs could help stimulate investment in radiation and bioterrorism countermeasures. Hollis-Eden expects to file a Neumune NDA in 2005.
You may also be interested in...
“Whistleblower” Suits Should Be Encouraged By Rx Manufacturers, Sen. Grassley Says
Schering-Plough’s Claritin settlement prompts letter from Grassley to Schering and 18 other manufacturers. Educating employees about the False Claims Act and their right to file suit is a “step in the right direction” to address fraud, he says.
PBMs Object To Real-Time Prior Authorization As Part Of E-Prescribing
Medco, Express Scripts and Cigna maintain that “automated” prior authorization is not feasible because it requires a discussion with the doctor. The PBMs recommend that HHS should support electronic transmission of prior authorization “where feasible.”
E-Prescriber Access To Non-Preferred Drug Listings Is Industry Concern
Physicians should not have to scroll or click through new windows to see non-preferred and off-formulary drugs, Pfizer, J&J tell the standards subcommittee of the National Committee on Vital & Health Statistics.